Business Description
Revolution Medicines Inc
NAICS : 325411
SIC : 2833
ISIN : US76155X1000
Share Class Description:
RVMD: Ordinary SharesTotal Employee Number:
883Compare
Compare
Traded in other countries / regions
RVMD.USA42Z.GermanyRVMD.Mexico1RVMD.Italy Index Membership
Russell 1000Russell 3000MSCI World IndexRussell 2000 IPO Date
2020-02-13Description
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 6.14 | |||||
Equity-to-Asset | 0.6 | |||||
Debt-to-Equity | 0.25 | |||||
Debt-to-EBITDA | -0.38 | |||||
Piotroski F-Score | 1/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -23 | |||||
3-Year EPS without NRI Growth Rate | -24 | |||||
3-Year FCF Growth Rate | -18.1 | |||||
3-Year Book Growth Rate | 3 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 40.66 | |||||
9-Day RSI | 49.81 | |||||
14-Day RSI | 54.58 | |||||
3-1 Month Momentum % | 19.01 | |||||
6-1 Month Momentum % | 83.82 | |||||
12-1 Month Momentum % | 393.89 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 11.38 | |||||
Quick Ratio | 11.38 | |||||
Cash Ratio | 11.12 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -29.6 | |||||
Shareholder Yield % | -5.07 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -96.11 | |||||
ROA % | -64.95 | |||||
ROIC % | -480.97 | |||||
3-Year ROIIC % | -499.14 | |||||
ROC (Joel Greenblatt) % | -1063.4 | |||||
ROCE % | -69.76 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 16.89 | |||||
Price-to-Tangible-Book | 17.36 | |||||
EV-to-EBIT | -23.85 | |||||
EV-to-EBITDA | -24.17 | |||||
EV-to-Forward-Revenue | 313.84 | |||||
EV-to-FCF | -25.67 | |||||
| Price-to-Net-Current-Asset-Value | 19.05 | |||||
| Price-to-Net-Cash | 19.82 | |||||
Earnings Yield (Greenblatt) % | -4.19 | |||||
FCF Yield % | -3.6 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:RVMD
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Revolution Medicines Inc Executives
DetailsGF Value™
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -8.82 | ||
| Beta | 1.9022 | ||
| 3-Year Sharpe Ratio | 1.4 | ||
| 3-Year Sortino Ratio | 2.88 | ||
| Volatility % | 54.33 | ||
| 14-Day RSI | 54.58 | ||
| 14-Day ATR ($) | 8.671837 | ||
| 20-Day SMA ($) | 206.55025 | ||
| 12-1 Month Momentum % | 393.89 | ||
| 52-Week Range ($) | 37.88 - 224.31 | ||
| Shares Outstanding (Mil) | 214.34 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Revolution Medicines Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Revolution Medicines Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-02-25 16:30 | In 178 days | ||
| Annual report for 2026 | 2027-02-25 | In 177 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-25 | In 177 days | ||
| Third quarter earnings conference call for 2026 | 2026-11-05 16:30 | In 66 days | ||
| Third quarter earnings results for 2026 | 2026-11-05 | In 65 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-05 16:30 | 193.46 (+5.41%) | ||
| Second quarter earnings results for 2026 | 2026-08-05 | 193.46 (+5.41%) | ||
| General meeting for 2026 | 2026-06-18 07:30 | 157.77 (+0.65%) | ||
| Positive RASolute 302 Results | 2026-05-31 19:00 | 157.57 (+1.23%) | ||
| First quarter earnings conference call for 2026 | 2026-05-06 16:30 | 147.21 (-0.98%) |
Show
Entries
Revolution Medicines Inc Frequently Asked Questions
What is Revolution Medicines Inc(RVMD)'s stock price today?
The current price of RVMD is $205.57. The 52 week high of RVMD is $224.31 and 52 week low is $37.88.
When is next earnings date of Revolution Medicines Inc(RVMD)?
The next earnings date of Revolution Medicines Inc(RVMD) is 2026-11-05 Est..
Does Revolution Medicines Inc(RVMD) pay dividends? If so, how much?
Revolution Medicines Inc(RVMD) does not pay dividend.
Guru Commentaries on NAS:RVMD
Parnassus Growth Equity Fund
Bullish
2026 Q2
What the manager wrote
Revolution Medicines’ lead drug candidate, daraxonrasib, has delivered strong late-stage clinical results in pancreatic cancer, with data suggesting it could become a new standard of care and support significant commercial potential, alongside additional opportunities in other cancers over time. This positions Revolution Medicines favorably within the health care sector, as it addresses a critical need in cancer treatment and demonstrates the potential for substantial growth.
Parnassus Mid Cap Growth Fund
Bullish
2026 Q2
What the manager wrote
We added Revolution Medicines, a late-stage clinical oncology company focused exclusively on developing targeted therapies for RAS-addicted cancers. This strategic addition reflects our belief in the company's innovative approach and potential for significant growth in a specialized market. We remain focused on finding innovative companies capable of growing through a range of macroeconomic environments, and Revolution Medicines fits this criterion well.
Press Release
Articles on Revolution Medicines Inc
Revolution Medicines (RVMD) Launches Rasonque Amid High Valuation and Mixed Insider Signals
5 days ago
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers